Merck, Roche to vie for Indian cancer market
PHARMA multinationals Merck KGaA and F Hoffmann La Roche are now proceeding to vie for catering to the the Rs 50 to Rs 100 crore colorectal cancer drug requirement in India with two products the US FDA approved in February.

Dr Reddy’s loses amlodipine maleate patent dispute with Pfizer
HYDERABAD-based Dr Reddy’s Laboratories (DRL) has announced that a US Appeals Court has reversed a lower court ruling and determined that the patent extension covering Pfizer’s Norvasc (amlodipine besylate) is applicable to Dr Reddy’s amlodipine maleate.

A strong patent system essential for economic growth: Shahani
A strong patents system is essential for India to facilitate wealth creation and investment in knowledge-based sectors, Novartis India chief Ranjit Shahani told reporters at a round table on intellectual property rights here.

Biocon’s IPO to be priced between Rs 270 to Rs 315
Biocon, the 25 year old India’s largest fully integrated biopharmaceutical company, is entering the capital market with its Initial Public Offering (IPO).

Biocon to launch insulin in Indian market soon
Biocon, focussed on statins, diabetic segment, immuno suppressants and oncology, will soon launch Insugen, a new product under its diabetic segment, in the first half of this year.

Promed Exports charts export oriented growth plan
SETTING an ambitious financial target of $75 million by year 2010, the New Delhi based pharmaceutical company Promed Exports has outlined an export thrust strategy.

Micro Labs launches new lipid lowering drug
Micro Labs is all set to launch a breakthrough drug for tighter control of cholesterol, for the first time in India.

Lincoln posts 100 per cent rise in profit
The Ahmedabad based, Lincoln Pharma has posted a 100 per cent rise in its profit.